An Elevation in the Serum Biomarker pTau-181 May Identify Progressive Supranuclear Palsy Pathology
Objective: To report three cases of progressive supranuclear palsy (PSP) with significantly elevated pTau-181 levels on serum testing. Background: According to the MDS-endorsed PSP Study…Identification of Alpha-synuclein Pathology in Primary Tauopathies by Seed Amplification Assay
Objective: To assess intravitam frequency and type of misfolded α-synuclein aggregates (syn-seeds) in participants with clinically defined primary tauopathies, such as progressive supranuclear palsy (PSP)…Exploring the Genetic Landscape of Corticobasal Syndrome in Asian Populations
Objective: We aimed to investigate the genetic spectrum of corticobasal syndrome (CBS) in a sizable Asian cohort. Background: CBS is a rare, rapidly progressive neurodegenerative…Plasma Phospho-Tau217 and Neuromelanin-Sensitive MRI as Candidate Biomarkers in Beta-Propeller Protein-Associated Neurodegeneration
Objective: To evaluate plasma phosphorylated tau at threonine 217 (pTau217) and neuromelanin-sensitive MRI (NM-MRI) as candidate biomarkers reflecting tau pathology and nigral iron deposition in…Neurological Wilson’s disease: another form of tauopathies?
Objective: The authors would hope to identify distribution of Tau protein within the brain of Wilson's disease patients by tau-targeted positron emission tomography (PET) tracers Background:…Quanti-tau-PET Study of PI‑2620 Tau-PET Quantification in Progressive Supranuclear Palsy
Objective: *Establish a quantitative analysis framework for PI‑2620 tau-PET in progressive supranuclear palsy (PSP);*Compare tau-PET uptake in PSP versus control subjects;*Assess correlations with clinical variables…Skin Tau Quantification as a Potential Degeneration Biomarker in Parkinson’s Disease
Objective: This cross-sectional observational study aims to quantify total skin Tau levels in Parkinson’s disease (PD) patients and explore their association with clinical symptoms. Background:…Fluid Biomarkers and the 4R-Tauopathies
Objective: To investigate the prevalence and clinical relevance of AD co-pathology, assessed through fluid biomarkers, in patients with clinical 4R-tauopathies. Background: 4R-tauopathies are neurodegenerative diseases…In Vivo 18F-Florzolotau Tau PET Imaging in Parkinson’s Disease with and without Probable REM Sleep Behavior Disorder
Objective: To investigate the distribution and potential influence of tau pathology in Parkinson’s disease (PD) patients with and without prodromal REM sleep behavior disorder (pRBD),…Latin American (LatAM) Progressive Supranuclear Palsy Consortium
Objective: To describe the demographic, clinical variants, and clinical profile of patients with probable or possible Progressive Supranuclear Palsy (PSP) enrolled in prospective cohorts from…
- 1
- 2
- 3
- …
- 16
- Next Page »